A Study of E6742 in Participants With Systemic Lupus Erythematosus
← catalyst calendarNCT07515014 · readout in 717 d
Sponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
256estimated
Sites
41
Countries
China, Japan, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-31 | actual | When the study began enrolling |
| Primary completion | 2028-08-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Interventions
- Drug: E6742
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants who Achieve a BICLA Response with Low Dose of OCS (Prednisone or Equivalent) at Week 24
measured At Week 24
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed